We focused on the novelty of APOL1 as a potential cancer marker whose low expression strongly associated to poor survival rate at metastatic stage of ccRCC (Figure 1D), considering that TGFBI had already been identified as oncogene in RCC (39). This evidence concerns the gene APOL1 and nonpapillary renal cell carcinoma.